Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Return on Invested Capital (2023 - 2025)

Historic Return on Invested Capital for Apellis Pharmaceuticals (APLS) over the last 5 years, with Q3 2025 value amounting to 0.24%.

  • Apellis Pharmaceuticals' Return on Invested Capital rose 11400.0% to 0.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.24%, marking a year-over-year increase of 11400.0%. This contributed to the annual value of 0.78% for FY2024, which is 20700.0% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Return on Invested Capital of 0.24% as of Q3 2025, which was up 11400.0% from 1.19% recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Return on Invested Capital registered a high of 38.66% during Q3 2022, and its lowest value of 7.77% during Q2 2022.
  • Its 5-year average for Return on Invested Capital is 0.27%, with a median of 1.63% in 2022.
  • Over the last 5 years, Apellis Pharmaceuticals' Return on Invested Capital had its largest YoY gain of 61500bps in 2023, and its largest YoY loss of -407300bps in 2023.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Return on Invested Capital stood at 7.59% in 2021, then skyrocketed by 67bps to 2.49% in 2022, then rose by 2bps to 2.43% in 2023, then soared by 71bps to 0.71% in 2024, then skyrocketed by 133bps to 0.24% in 2025.
  • Its last three reported values are 0.24% in Q3 2025, 1.19% for Q2 2025, and 0.95% during Q1 2025.